Fuente: PubMed "nature biotechnology" Dermatol Ther (Heidelb). 2026 Jul 30. doi: 10.1007/s13555-026-01865-0. Online ahead of print.ABSTRACTINTRODUCTION: Atopic dermatitis (AD), a chronic inflammatory condition, is the leading cause of global burden from skin disease. Optimal targets for clinician-reported outcomes (ClinROs) and patient-reported outcomes (PROs), including minimal disease activity (MDA; defined as simultaneous achievement of ≥ 1 optimal ClinRO and ≥ 1 optimal PRO), were established following the Aiming High in Eczema/Atopic Dermatitis (AHEAD) initiative. This study evaluated the impact of MDA achievement on flare activity, healthcare resource utilization, and patient-reported disease control in adults with moderate-to-severe AD.METHODS: This retrospective post hoc analysis used data from the real-world cross-sectional MEASURE-AD study and included adults with moderate-to-severe AD across 28 countries. Three definitions were used to identify achievement of MDA. Outcomes were measured using patient-reported questionnaires evaluating flare activity and healthcare resource utilization over the preceding 6 months, as well as patient-reported disease control assessed at the time of the questionnaire. Statistical analyses compared patients achieving MDA targets with non-MDA groups using Kruskal-Wallis tests.RESULTS: Patients achieving MDA experienced fewer flares (means ranging from 0.8 to 1.4) compared with non-MDA groups (3.8-9.8) over the preceding 6 months. Flares were shorter in duration, with 9.9-13.4% of patients who achieved MDA reporting flares longer than 7 days compared with 26.4-51.1% of patients across non-MDA groups. Patients who met neither optimal ClinRO or PRO reported a 2.2- to 2.7-fold increase in average number of healthcare visits compared with MDA groups. More patients who achieved MDA indicated complete agreement that their AD was effectively controlled (86.7-94.2%) compared with those who did not achieve MDA (19.2-74.1%).CONCLUSIONS: Achievement of MDA in patients with moderate-to-severe AD was associated with less frequency and duration of flares, reduced healthcare resource utilization, and increased patient-reported disease control compared with those who did not achieve MDA. These findings emphasize the importance of holistic assessments when evaluating treatment outcomes in AD.TRIAL REGISTRATION: ClinicalTrials.gov Identifiers NCT03569293 (Measure Up 1), NCT03607422 (Measure Up 2), and NCT03568318 (AD Up).PMID:42530735 | DOI:10.1007/s13555-026-01865-0